Concentric Analgesics Begins Clinical Trial of CA-008 for Post-Surgical Pain Following Bunionectomy.
M2 PHARMA-November 3, 2017-Concentric Analgesics Begins Clinical Trial of CA-008 for Post-Surgical Pain Following Bunionectomy
(C)2017 M2 COMMUNICATIONS
- US-based clinical-stage biopharmaceutical company Concentric Analgesics, Inc. has initiated a Phase 1b clinical trial with CA-008, a proprietary, water-soluble prodrug that converts into capsaicin, a potent TRPV-1 agonist, the company said.
Capsaicin, which has a long history of use as a topical analgesic, selectively and reversibly desensitizes pain-conducting nerve fibers (C-fiber nociceptors).
The Phase 1b study is a randomized, double-blind clinical trial, targeting approximately 32 patients undergoing bunionectomy. The goal of the single, ascending-dose trial is to examine the safety, tolerability, and pharmacokinetics of CA-008.
In addition to the company's post-surgical program, Concentric expects to complete a series of pre-clinical research studies by the end of 2017 for CA-011, its program in osteoarthritis.
Concentric Analgesic's lead investigational product candidates, CA-008 and CA-011, convert into capsaicin, a potent TRPV-1 agonist that evokes an initial neuronal excitation that is followed by a durable refractory state to provide long lasting analgesia.
Privately-held Concentric Analgesics is focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 3, 2017|
|Previous Article:||Eleven Biotherapeutics Anticipates Proceeds of Underwritten Public Offering of USD 8m.|
|Next Article:||Care.com Adds Dan Yoo to Board of Directors.|